Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer

NCT00732082 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT00732082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00732082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients With Advanced Pancreas Cancer
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Terminated
Start date
February 28, 2009
Completion date
September 30, 2012
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms